FDA to use AI for faster drug trials

The U.S. Food and Drug Administration is set to implement artificial intelligence to accelerate the drug development process. By gaining real-time visibility into ongoing clinical trials, the agency aims to significantly reduce the time required for testing new medicines. This initiative is expected to streamline regulatory pathways and bring potentially life-saving treatments to market more efficiently.